Streetbeat News

Products Services

PGEN

Precigen shares are trading higher following positive study data for PRGN-2012 for recurrent respiratory papillomatosis patients. Stifel has maintained a Buy rating on the stock and raised its price target from $7 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:39 pm

REPL

Replimune Group shares are trading higher following the presentation of clinical data from its RP1 and RP2 programs at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:36 pm

LLY

QurAlis has granted Eli Lilly an exclusive global license for QRL-204, a precision therapy aimed at restoring UNC13A function in ALS and FTD. The collaboration will leverage QurAlis' expertise in ALS and ASO development to advance QRL-204 and next-generation compounds.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:35 pm

GILD

RCUS

Gilead Sciences and Arcus Biosciences released positive data from their Phase 2 EDGE-Gastric and ARC-9 studies, showing promising results in gastric and colorectal cancers. Despite recent setbacks in bladder cancer studies, these new findings could bolster investor confidence.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:35 pm

LQDA

Liquidia shares are trading higher following a favorable ruling by the U.S. District Court for the District of Delaware, which denied United Therapeutics' request to block the launch of YUTREPIA.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:28 pm

ERJ

Mexicana de Aviación has ordered 20 Embraer E2 aircraft, including 10 E190-E2 and 10 E195-E2 jets, with deliveries starting in Q2 2025. This deal marks Mexicana as the first E2 operator in Mexico, emphasizing the aircraft's low operating costs and fuel efficiency.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:20 pm

AGIO

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) shares surged after the Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary and secondary endpoints, showing significant reduction in transfusion burden compared to placebo. The company plans to submit a U.S. marketing application for Pyrukynd (mitapivat) by the end of 2024.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:11 pm

AMC

GME

KOSS

Roaring Kitty's return has sparked a significant rally in meme stocks, particularly AMC Entertainment Holdings and GameStop. AMC surged 25.6% in pre-market trading and saw a near 80% increase following Keith Gill's disclosure of a substantial position in GameStop. Despite the initial surge, AMC's share price has settled at $4.92, with mixed technical indicators suggesting both short-term bullishness and long-term challenges. The company's future performance will be closely watched as it navigates renewed attention and operational challenges.

Portfolio Pulse from Surbhi Jain

June 03, 2024 | 4:04 pm

CRNX

Crinetics Pharmaceuticals presented new data from its Phase 3 PATHFNDR-2 trial at ENDO 2024, showing promising results for its oral, once-daily treatment for acromegaly, paltusotine. The data indicate rapid and sustained IGF-1 responses and fewer symptom exacerbations compared to standard care. Crinetics plans to complete the NDA submission for paltusotine in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:02 pm

JNJ

Johnson & Johnson announced long-term data from the Phase 1/2 MajesTEC-1 study of Tecvayli, showing sustained deep and durable responses in patients with relapsed or refractory multiple myeloma. The study demonstrated a 63% overall response rate and a 46% complete response rate. Safety profiles remained consistent, and the use of tocilizumab reduced the incidence of cytokine release syndrome.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:01 pm